INR 883.15
(1.65%)
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2023 | 71.79 Billion INR | 18.31% |
2022 | 60.68 Billion INR | -30.58% |
2021 | 87.41 Billion INR | -2.38% |
2020 | 89.55 Billion INR | -25.23% |
2019 | 119.76 Billion INR | 1.46% |
2018 | 118.03 Billion INR | 29.29% |
2017 | 91.29 Billion INR | 12.65% |
2016 | 81.04 Billion INR | 78.95% |
2015 | 45.29 Billion INR | -2.11% |
2014 | 46.26 Billion INR | 5.07% |
2013 | 44.03 Billion INR | 2.2% |
2012 | 43.08 Billion INR | 15.97% |
2011 | 37.15 Billion INR | 59.53% |
2010 | 23.28 Billion INR | 12.46% |
2009 | 20.7 Billion INR | -2.58% |
2008 | 21.25 Billion INR | 42.81% |
2007 | 14.88 Billion INR | 31.53% |
2006 | 11.31 Billion INR | 29.55% |
2005 | 8.73 Billion INR | 13.9% |
2004 | 7.66 Billion INR | -4.85% |
2003 | 8.05 Billion INR | 0.0% |
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2023 Q2 | 49.38 Billion INR | 0.0% |
2023 Q3 | - INR | -100.0% |
2023 FY | 71.79 Billion INR | 18.31% |
2023 Q4 | 71.79 Billion INR | 0.0% |
2023 Q1 | - INR | -100.0% |
2022 Q3 | - INR | -100.0% |
2022 Q2 | 68.61 Billion INR | 0.0% |
2022 FY | 60.68 Billion INR | -30.58% |
2022 Q1 | - INR | -100.0% |
2022 Q4 | 60.68 Billion INR | 0.0% |
2021 Q2 | 92.95 Billion INR | 0.0% |
2021 Q1 | - INR | -100.0% |
2021 FY | 87.41 Billion INR | -2.38% |
2021 Q4 | 87.41 Billion INR | 0.0% |
2021 Q3 | - INR | -100.0% |
2020 Q2 | 109.16 Billion INR | 0.0% |
2020 Q4 | 89.55 Billion INR | 0.0% |
2020 FY | 89.55 Billion INR | -25.23% |
2020 Q1 | - INR | -100.0% |
2020 Q3 | - INR | -100.0% |
2019 Q4 | 119.76 Billion INR | 0.0% |
2019 Q3 | - INR | -100.0% |
2019 Q2 | 114.23 Billion INR | 0.0% |
2019 FY | 119.76 Billion INR | 1.46% |
2019 Q1 | - INR | -100.0% |
2018 Q3 | - INR | -100.0% |
2018 Q1 | - INR | -100.0% |
2018 FY | 118.03 Billion INR | 29.29% |
2018 Q4 | 118.03 Billion INR | 0.0% |
2018 Q2 | 89.5 Billion INR | 0.0% |
2017 Q3 | - INR | -100.0% |
2017 Q4 | 91.29 Billion INR | 0.0% |
2017 Q2 | 87.05 Billion INR | 0.0% |
2017 Q1 | - INR | -100.0% |
2017 FY | 91.29 Billion INR | 12.65% |
2016 Q4 | 81.04 Billion INR | 0.0% |
2016 FY | 81.04 Billion INR | 78.95% |
2016 Q3 | - INR | -100.0% |
2016 Q2 | 53.66 Billion INR | 0.0% |
2016 Q1 | - INR | -100.0% |
2015 Q4 | 45.29 Billion INR | 0.0% |
2015 FY | 45.29 Billion INR | -2.11% |
2015 Q2 | 46.05 Billion INR | 0.0% |
2015 Q1 | - INR | -100.0% |
2015 Q3 | - INR | -100.0% |
2014 Q4 | 46.26 Billion INR | 0.0% |
2014 FY | 46.26 Billion INR | 5.07% |
2014 Q3 | - INR | -100.0% |
2014 Q2 | 43.97 Billion INR | 0.0% |
2014 Q1 | - INR | -100.0% |
2013 FY | 44.03 Billion INR | 2.2% |
2013 Q2 | 46.65 Billion INR | 0.0% |
2013 Q1 | - INR | -100.0% |
2013 Q3 | - INR | -100.0% |
2013 Q4 | 44.03 Billion INR | 0.0% |
2012 Q4 | 43.08 Billion INR | 0.0% |
2012 FY | 43.08 Billion INR | 15.97% |
2012 Q2 | 39.79 Billion INR | 0.0% |
2012 Q3 | - INR | -100.0% |
2011 FY | 37.15 Billion INR | 59.53% |
2011 Q4 | 37.15 Billion INR | 0.0% |
2010 FY | 23.28 Billion INR | 12.46% |
2009 FY | 20.7 Billion INR | -2.58% |
2008 FY | 21.25 Billion INR | 42.81% |
2007 FY | 14.88 Billion INR | 31.53% |
2006 FY | 11.31 Billion INR | 29.55% |
2005 FY | 8.73 Billion INR | 13.9% |
2004 FY | 7.66 Billion INR | -4.85% |
2003 FY | 8.05 Billion INR | 0.0% |
Name | Total Liabilities | Total Liabilities Difference |
---|---|---|
Hester Biosciences Limited | 3.59 Billion INR | -1897.151% |
RPG Life Sciences Limited | 1.38 Billion INR | -5101.565% |
Suven Pharmaceuticals Limited | 2.03 Billion INR | -3429.2% |
Ipca Laboratories Limited | 33.74 Billion INR | -112.762% |
Aarti Drugs Limited | 11.5 Billion INR | -524.061% |
Aarti Pharmalabs Limited | 8.25 Billion INR | -770.132% |
Albert David Limited | 1.15 Billion INR | -6142.213% |
Alembic Limited | 1.43 Billion INR | -4913.058% |
Alkem Laboratories Limited | 48.6 Billion INR | -47.705% |
Alembic Pharmaceuticals Limited | 16.27 Billion INR | -341.151% |
Bafna Pharmaceuticals Limited | 652.27 Million INR | -10906.333% |
Bajaj HealthCare Limited | 4.86 Billion INR | -1374.875% |
Biofil Chemicals and Pharmaceuticals Limited | 288.79 Million INR | -24758.812% |
Brooks Laboratories Limited | 248.6 Million INR | -28778.404% |
Eris Lifesciences Limited | 38.26 Billion INR | -87.603% |
FDC Limited | 3.7 Billion INR | -1835.508% |
Glenmark Life Sciences Limited | 5.18 Billion INR | -1285.705% |
Gufic Biosciences Limited | 5.59 Billion INR | -1182.043% |
Hikal Limited | 12.99 Billion INR | -452.463% |
Ind-Swift Laboratories Limited | 2.28 Billion INR | -3035.76% |
Ind-Swift Limited | 13.45 Billion INR | -433.652% |
Innova Captab Limited | 4.89 Billion INR | -1365.182% |
IOL Chemicals and Pharmaceuticals Limited | 6.32 Billion INR | -1034.352% |
Jagsonpal Pharmaceuticals Limited | 296.76 Million INR | -24091.94% |
Jubilant Pharmova Limited | 61.27 Billion INR | -17.166% |
Kilitch Drugs (India) Limited | 643.88 Million INR | -11049.852% |
Laurus Labs Limited | 42.71 Billion INR | -68.074% |
Lincoln Pharmaceuticals Limited | 1.07 Billion INR | -6581.153% |
Lupin Limited | 96.23 Billion INR | 25.401% |
Mangalam Drugs & Organics Limited | 1.97 Billion INR | -3532.627% |
Medico Remedies Limited | 438.24 Million INR | -16281.742% |
Morepen Laboratories Limited | 4.45 Billion INR | -1509.762% |
Nectar Lifesciences Limited | 11.21 Billion INR | -539.967% |
Orchid Pharma Limited | 3.84 Billion INR | -1767.6% |
Procter & Gamble Health Limited | 2.56 Billion INR | -2703.061% |
Sigachi Industries Limited | 2.53 Billion INR | -2736.21% |
Solara Active Pharma Sciences Limited | 14.09 Billion INR | -409.459% |
Sun Pharmaceutical Industries Limited | 183.56 Billion INR | 60.891% |
Themis Medicare Limited | 1.88 Billion INR | -3703.528% |
Unichem Laboratories Limited | 8.06 Billion INR | -789.698% |
Vaishali Pharma Limited | 371.16 Million INR | -19242.445% |
Venus Remedies Limited | 1.39 Billion INR | -5054.509% |
Wanbury Limited | 3.15 Billion INR | -2175.126% |
Windlas Biotech Limited | 1.76 Billion INR | -3972.843% |
ZIM Laboratories Limited | 2.08 Billion INR | -3350.274% |
Sakar Healthcare Limited | 1.26 Billion INR | -5582.984% |
Aurobindo Pharma Limited | 152.2 Billion INR | 52.833% |
Divi's Laboratories Limited | 18.99 Billion INR | -278.052% |
AstraZeneca Pharma India Limited | 3.66 Billion INR | -1860.936% |
Mankind Pharma Limited | 23.87 Billion INR | -200.704% |
Sequent Scientific Limited | 8.27 Billion INR | -767.656% |
Neuland Laboratories Limited | 5.49 Billion INR | -1205.65% |
J. B. Chemicals & Pharmaceuticals Limited | 10.7 Billion INR | -570.452% |
Glenmark Pharmaceuticals Limited | 65.11 Billion INR | -10.261% |
Amrutanjan Health Care Limited | 783.82 Million INR | -9059.199% |
Wockhardt Limited | 39.87 Billion INR | -80.065% |
Bal Pharma Limited | 2.51 Billion INR | -2758.786% |
Dr. Reddy's Laboratories Limited | 106.96 Billion INR | 32.885% |
Bliss GVS Pharma Limited | 2.1 Billion INR | -3304.318% |
Par Drugs and Chemicals Limited | 159.79 Million INR | -44828.688% |
Caplin Point Laboratories Limited | 3.5 Billion INR | -1947.923% |
Shilpa Medicare Limited | 12.93 Billion INR | -455.13% |
Valiant Laboratories Limited | 1.05 Billion INR | -6683.96% |
Ajanta Pharma Limited | 10.71 Billion INR | -570.308% |
Aarey Drugs & Pharmaceuticals Limited | 1.72 Billion INR | -4068.652% |
Granules India Limited | 22.95 Billion INR | -212.759% |
Medicamen Biotech Limited | 940.36 Million INR | -7534.466% |
Syncom Formulations (India) Limited | 1.16 Billion INR | -6061.288% |
Piramal Enterprises Limited | 560.47 Billion INR | 87.191% |
Torrent Pharmaceuticals Limited | 82.05 Billion INR | 12.502% |
NATCO Pharma Limited | 10.53 Billion INR | -581.656% |
Suven Life Sciences Limited | 148.62 Million INR | -48205.421% |
Krebs Biochemicals & Industries Limited | 2.97 Billion INR | -2314.058% |
Strides Pharma Science Limited | 37.68 Billion INR | -90.528% |
Indoco Remedies Limited | 10.34 Billion INR | -594.159% |
Alpa Laboratories Limited | 307.12 Million INR | -23275.727% |
Lasa Supergenerics Limited | 541.92 Million INR | -13147.59% |
Sun Pharma Advanced Research Company Limited | 3.89 Billion INR | -1744.178% |